JIXING Announces the Appointment of Kun Wu as the Chief Commercial Officer
Kun brings strong biopharmaceutical expertise and will be responsible to build JIXING’s commercial strategy & organization
SHANGHAI, China, March 31, 2022 – Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announces the appointment of Kun Wu as the Chief Commercial Officer. Kun will be based in Shanghai, China and will report to Joseph Romanelli, CEO of JIXING. In this position, Kun will be responsible for developing JIXING’s commercial strategy and building a world-class team to drive the commercialization of its growing product portfolio.
Kun has more than 26 years of pharmaceutical experience with most of his career at Pfizer. Most recently, he served as the China Chief Operating Officer at Pfizer Biopharma Group, leading a team with 5,000 people including Sales, Marketing, Key Accounts, Commercial and Business Operations. Prior to this role, Kun served as the China Country Lead at Pfizer Biopharma Group and as the China Country Lead of Pfizer Innovative Healthcare where he led the commercial team to achieve excellent performance and successfully launched multiple blockbuster products in the market.
“Kun is an accomplished industry leader in China, and we are pleased to welcome him to JIXING. He has strong biopharmaceutical expertise and proven capabilities to build a market leading commercial team,” said Joseph Romanelli, CEO of JIXING. “As a company, our goal is to bring disruptive science to help improve upon the standard of care for patients in China. To achieve this goal, we have built a growing pipeline of 5 novel assets in late clinical stage targeting 7 indications. Today’s appointment of Kun as our Chief Commercial Officer begins our transition as a company to build an organization that can ensure an effective go-to-market and launch strategy so that our customers and patients can ultimately benefit from our innovation.”
"I am very excited to join JIXING and look forward to working with the leadership team to build the company’s commercial organization,” said Kun Wu, newly appointed Chief Commercial Officer of JIXING. “There are high unmet needs in the Cardiovascular and Ophthalmology disease areas where JIXING has leading assets at late clinical stage. I strongly believe that our novel therapeutics can improve the life of many patients in China.”
JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients in China with serious and life-threatening diseases. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients in Greater China.